ResMed
891 hedge funds and large institutions have $19.4B invested in ResMed in 2026 Q2 according to their latest regulatory filings, with 93 funds opening new positions, 309 increasing their positions, 363 reducing their positions, and 138 closing their positions.
1.89% more ownership
Funds ownership: 66.8% → 68.69% (+1.9%)
6% less funds holding
Funds holding: 945 → 891 (-54)
11% less capital invested
Capital invested by funds: $21.8B → $19.4B (-$2.4B)
15% less repeat investments, than reductions
Existing positions increased: 309 | Existing positions reduced: 363
33% less first-time investments, than exits
New positions opened: 93 | Existing positions closed: 138
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
57% less call options, than puts
Call options by funds: $67.2M | Put options by funds: $157M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$154M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$141M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$117M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$116M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$91.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$157M |
| 2 |
Bank of New York Mellon
New York
|
-$151M |
| 3 |
Amundi
Paris,
France
|
-$94.9M |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$90.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$77.7M |
RMD Hedge Fund Activity: Q2 2026 in Review
891 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2026, worth a combined $19.4B — down 11% from $21.8B a quarter earlier.
Sellers outnumbered buyers: 138 funds closed out of RMD and 93 opened new positions — a net loss of 45 holders — while 363 trimmed existing stakes and 309 added.
The largest buyer was First Trust Advisors, adding an estimated $154M. The largest seller was Morgan Stanley, cutting an estimated $157M.
- 891 institutional investors held ResMed (RMD) as of Q2 2026, down from 945 in Q1 2026.
- Funds reported $19.4B of ResMed stock for Q2 2026, down 11% quarter-over-quarter.
- 93 funds opened new ResMed positions in Q2 2026 and 138 closed out, a net change of -45 holders.
- The largest ResMed buyer in Q2 2026 was First Trust Advisors, an estimated $154M added.
- The largest ResMed seller in Q2 2026 was Morgan Stanley, an estimated $157M sold.
Based on aggregated 13F filings for Q2 2026.